文献速递抗栓抗凝管理肝肾功能剂量调整

比伐芦定抗凝延迟达标的风险因素与结局:回顾性队列研究

Risk Factors and Outcomes Associated with Prolonged Subtherapeutic Anticoagulation with Bivalirudin: A Retrospective Cohort Study.
PubMed 文献 · Pharmacotherapy · 2019-10-29

本研究为回顾性队列研究,纳入18至89岁接受比伐芦定治疗至少24小时的患者,评估未能实现早期治疗性抗凝(ETA,24小时内连续两次aPTT达标)的相关因素及临床结局。结果显示,不遵循给药方案和肌酐清除率≥60 ml/min与ETA失败显著相关,而年龄增长与ETA达标相关;ETA失败与血栓栓塞风险增加4倍相关。

要点

  • 不遵循给药方案和肌酐清除率≥60 ml/min是比伐芦定ETA失败的独立危险因素。
  • 年龄增长与更高的ETA达标率相关(OR 0.98)。
  • ETA失败与血栓栓塞风险增加4倍相关,需加强监测。

核心结论

  • 年轻、肾功能正常及不遵循给药方案与比伐芦定早期治疗性抗凝失败风险增加相关,并导致血栓栓塞风险升高。

研究设计与样本

  • 回顾性队列研究,纳入18至89岁接受比伐芦定治疗至少24小时的患者。

主要发现

  • 不遵循给药方案(OR 1.7,95%CI 1.07-2.71)和肌酐清除率≥60 ml/min(OR 2.99,95%CI 1.12-7.97)与ETA失败显著相关。
  • 年龄增长(OR 0.98,95%CI 0.97-0.99)与ETA达标显著相关。
  • ETA失败与血栓栓塞风险增加4倍相关。

关键数值与推荐

  • ETA定义为24小时内连续两次aPTT达到治疗范围。

临床怎么用

  • 对年轻、肾功能正常及不遵循给药方案的患者,应加强aPTT监测以确保比伐芦定早期达标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bivalirudin, a direct thrombin inhibitor, is a treatment option for the management of heparin-induced thrombocytopenia (HIT) and other coagulation disorders. To date, no published studies have identified patients at risk for or the consequence of subtherapeutic bivalirudin therapy. OBJECTIVES: The primary objective was to identify factors associated with failure to achieve early therapeutic anticoagulation (ETA) with bivalirudin, defined as achievement of two consecutive therapeutic activated partial thromboplastin times (aPTTs) within 24 hours. Secondary objectives included evaluating whether failure to achieve ETA was a risk factor for clinical outcomes of interest including thromboembolism, hemorrhage, and mortality. PATIENTS/METHODS: This was a retrospective cohort study. Patients between the ages of 18 and 89 years treated with bivalirudin for 24 hours or longer were identified and classified as either achieving or failing to achieve ETA. RESULTS: Nonadherence to the dosing protocol (odds ratio [OR] 1.7, 95% confidence interval [CI] 1.07-2.71) and creatinine clearance (CrCl) of 60 ml/min or greater (OR 2.99, 95% CI 1.12-7.97) were significantly associated with failure to achieve ETA in univariate analyses. Conversely, increasing age (OR 0.98, 95% CI 0.97-0.99) was significantly associated with achievement of ETA. Failure to achieve ETA was associated with a 4-fold increase in the odds of thromboembolism. CONCLUSIONS: Younger age, normal renal function, and nonadherence to the dosing protocol when targeting therapeutic anticoagulation is associated with increased risk of failure to achieve ETA. This confers an elevated risk of thromboembolism when using bivalirudin for the management of HIT or other coagulation disorders.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Orzel LA, Abel EE, Blais DM, et al. Risk Factors and Outcomes Associated with Prolonged Subtherapeutic Anticoagulation with Bivalirudin: A Retrospective Cohort Study. Pharmacotherapy. 2019. PMID: 31587337. doi:10.1002/phar.2335

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。